The dataset included plasma proglucagon data for ~40,000 individuals, ~15 years follow-up data on incident type 2 diabetes development, amino acid quantification for ~230,000 individuals, liver fat quantification for ~35,000 individuals, and exome sequencing, allowing investigations of the potential impact of glucagon receptor variants on clinical features. This evidence concerns the gene GCGR and type 2 diabetes mellitus.